What is the standard dosing protocol for BPC-157 + TB-500 Blend?

Conventional BPC-157 + TB-500 Blend dosing is 250 mcg BPC-157 + 2 mg TB-500 per dose 2-3x weekly via subq. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What route should I use for BPC-157 + TB-500 Blend?

BPC-157 + TB-500 Blend is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

How long until I see results from BPC-157 + TB-500 Blend?

Acute effects from BPC-157 + TB-500 Blend appear within the first week for downstream physiological adaptation. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What should I look for in BPC-157 + TB-500 Blend sourcing and quality?

Acceptable BPC-157 + TB-500 Blend certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching Variable (combined formulation), endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the mechanism of action of BPC-157 + TB-500 Blend?

BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling. The combination targets both vascular regrowth and cellular reorganisation. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the evidence base for BPC-157 + TB-500 Blend?

BPC-157 + TB-500 Blend's evidence base sits at preclinical + clinical anecdote. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Home/ Compounds/ BPC-157 + TB-500 Blend

BPC-157 + TB-500 Blend

Longevity

Healthspan-relevant evaluation of BPC-157 + TB-500 Blend starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling The combination targets both vascular regrowth and cellular reorganisation.. The BPC-157 ~4 hr; TB-500 ~2-3 days pharmacokinetic profile, the cycle-based 250 mcg BPC-157 + 2 mg TB-500 per dose 2-3x weekly dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Mitochondrial BiogenesisNAD+ MetabolismCellular ReprogrammingStem Cell FunctionSenescence Modulation

Key Takeaways

Longevity lens: BPC-157 + TB-500 Blend maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 250 mcg BPC-157 + 2 mg TB-500 per dose 2-3x weekly dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling. The combination targets both vascular regrowth and cellular reorganisation. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for BPC-157 + TB-500 Blend.

Mapping to the hallmarks of aging

BPC-157 + TB-500 Blend's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. BPC-157 contributes angiogenesis (VEGFR2) and FAK-paxillin signalling; TB-500 (a thymosin-β4 fragment) contributes actin sequestration, cell migration, and broader tissue remodelling. The combination targets both vascular regrowth and cellular reorganisation. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after BPC-157 + TB-500 Blend cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cycle-based versus continuous dosing

BPC-157 + TB-500 Blend's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Longevity / Hallmarks of Aging Applications

Inflammaging

For inflammaging as a longevity-relevant endpoint, BPC-157 + TB-500 Blend is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Cellular Reprogramming

Cellular Reprogramming maps to one of the hallmarks of aging and is one of the dimensions on which BPC-157 + TB-500 Blend is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Nutrient Sensing

BPC-157 + TB-500 Blend's contribution to nutrient sensing as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Mitochondrial Biogenesis

For mitochondrial biogenesis as a longevity-relevant endpoint, BPC-157 + TB-500 Blend is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	250 mcg BPC-157 + 2 mg TB-500 per dose	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	150 mcg BPC-157 + 2 mg TB-500 per dose	4–6 weeks initial cycle
Longevity focus	SubQ	250 mcg BPC-157 + 2 mg TB-500 per dose	2-3x weekly
Maintenance phase	SubQ	175 mcg BPC-157 + 2 mg TB-500 per dose	Ongoing with periodic pauses

Dose timing for BPC-157 + TB-500 Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

BPC-157 + TB-500 Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

BPC-157 + TB-500 Blend + Epithalon: Identified by Khavinson in St. Pairs naturally with BPC-157 + TB-500 Blend's mechanism in longevity / hallmarks of aging protocols.
BPC-157 + TB-500 Blend + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with BPC-157 + TB-500 Blend's mechanism in longevity / hallmarks of aging protocols.
BPC-157 + TB-500 Blend + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with BPC-157 + TB-500 Blend's mechanism in longevity / hallmarks of aging protocols.
BPC-157 + TB-500 Blend + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with BPC-157 + TB-500 Blend's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Both components banned FDA: Unapproved Research: Preclinical + clinical anecdote

Combined profile of both peptides. Avoid in active cancer.

Lens-specific safety considerations for longevity / hallmarks of aging use of BPC-157 + TB-500 Blend: Combined profile of both peptides. Avoid in active cancer. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

BPC 157 cytoprotection

PMID 10404425

Supporting

Thymosin β4 and tissue regeneration

PMID 19737543

BPC-157 + TB-500 Blend vs Related Peptides

Compound	Profile	Onset	Best For
BPC-157 + TB-500 Blend	Tissue repair blend	BPC-157 ~4 hr; TB-500 ~2-3 days	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. BPC-157 + TB-500 Blend fits this framework with cycle lengths typical for its compound class.

Does BPC-157 + TB-500 Blend actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether BPC-157 + TB-500 Blend measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

How do I know if BPC-157 + TB-500 Blend is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). BPC-157 + TB-500 Blend contributes to its specific hallmark layer in this multi-component framework.

Should I cycle BPC-157 + TB-500 Blend?

Standard cycle for BPC-157 + TB-500 Blend is 8–12 weeks of 2-3x weekly 250 mcg BPC-157 + 2 mg TB-500 per dose dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to BPC-157 + TB-500 Blend's BPC-157 ~4 hr; TB-500 ~2-3 days half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What is the regulatory status of BPC-157 + TB-500 Blend?

BPC-157 + TB-500 Blend regulatory status: Unapproved in the United States; WADA status both components banned; research level preclinical + clinical anecdote. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Clinical Protocol

Start a BPC-157 + TB-500 Blend Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified BPC-157 + TB-500 Blend and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: Variable (combined formulation)
Half-life: BPC-157 ~4 hr; TB-500 ~2-3 days
WADA: Both components banned
FDA: Unapproved
Research: Preclinical + clinical anecdote

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 + TB-500 Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for BPC-157 + TB-500 Blend

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised